Description

The International Rehab and Global Health Community will bring a dynamic discussion and networking event for this year's Member May Session. This session will dive into some of the most pressing and thought-provoking topics in international rehabilitation, fostering critical dialogue and collaboration among professionals passionate about global physiatry. Topics will include:  1. Decolonizing global PM&R -- challenging traditional power structures and fostering more equitable partnerships, ethical engagement in global health, and shifting towards locally driven leadership in rehabilitation efforts. What can we learn from cross-cultural perspectives on disability and rehabilitation, and how do these insights shape patient-centered care? 2. Evolution of global rehabilitation education and training -- addressing how curricula can better reflect diverse, international needs while equipping the next generation of physiatrists, with particular focus on the role of artificial intelligence and its influence on reshaping global rehabilitation, access, and innovation.   

Our session will also have a safe space for discussion with regards to current US policies and international relations and the impact on rehabilitation initiatives abroad, medical missions, funding, and partnerships in global health. Whether you're a seasoned global health practitioner or newly engaged in international rehab, this session offers a space to exchange ideas, build connections, and spark meaningful change in the field.

Learning Objectives

• Learning Objective 1: Critically examine the concept of decolonizing global PM&R by identifying key principles, challenges, and strategies for fostering equitable partnerships and locally led rehabilitation initiatives.
• Learning Objective 2: Explore cross-cultural perspectives on disability and rehabilitation to better understand how social, cultural, and historical contexts shape care delivery and patient experiences globally.
• Learning Objective 3: Identify strategies to improve global rehabilitation education and training programs that align with local health needs, promote interdisciplinary collaboration, and empower the next generation of international rehab professionals.
• Learning Objective 4: Explore Technological Innovations: Evaluate the role of artificial intelligence in expanding access to rehabilitation services in resource-limited settings, while addressing ethical considerations and potential disparities.
• Learning Objective 5: Analyze Policy Impacts on Medical Missions: Understand the implications of current U.S. administration policies on international medical missions, including visa regulations, funding restrictions, and global partnerships.

Accreditation Statement
The American Academy of Physical Medicine and Rehabilitation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit
The American Academy of Physical Medicine and Rehabilitation (AAPM&R) designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.  

Financial Disclosures
AAPM&R requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest, which is any entity producing, marketing, re-selling or distributing health care goods or services consumed by, or used on, patients. Disclosures are made in written form prior to the start of the educational activity and any potential conflicts of interest that exist are resolved prior to the start of the activity through AAPM&R’s Conflict of Interest Disclosure and Resolution Policy Process. Individuals in a position to control content and their disclosed financial relationships are listed below.

Faculty
Session Director: Nina Carmela Tamayo, DO, MS, MPH, FAAPMR, Disclosed no relevant financial relationships.    
Kaile Eison, DO, FAAPMR, Disclosed no relevant financial relationships.

AAPM&R Medical Education Committee
John C. Cianca, MD: Ownership or partnership with Musculoskeletal Ultrasound Consultants, LLC.
Karen P. Barr, MD: Disclosed no relevant financial relationships.
Rachel A. Brakke Holman, MD: Disclosed no relevant financial relationships.
Joseph E. Burris, MD: Serves on the Speakers Bureau for, and received clinical research grants from Allergan.
David S. Cheng, MD: Disclosed no relevant financial relationships.
Theresa A. Gillis, MD: Disclosed no relevant financial relationships.
Kevin N. Hakimi, MD: Disclosed no relevant financial relationships.
Matthew T. Haas, MD: Disclosed no relevant financial relationships.
R.Samuel Mayer, MD: Royalties from Demos Medical Publishing.
Ameet S. Nagpal, MD MS MEd: Disclosed no relevant financial relationships.
Sunil Sabharwal, MD: Royalities from Demos Publishing; board member, American Board of Physical Medicine and Rehabilitation.
Sarah M. Smith, MD: Disclosed no relevant financial relationships.
Stephanie Tow, MD: Disclosed no relevant financial relationships.
Kevin R. VIncent, MD, PhD: Disclosed no relevant financial relationships.

AAPM&R CME Committee
Karen P. Barr, MD: Disclosed no relevant financial relationships.
Cherry C. Junn, MD: Disclosed no relevant financial relationships.
Sheryl R. Levin, MD: Disclosed no relevant financial relationships.
Kentaro Onishi, DO: Disclosed no relevant financial relationships.
Evan R. Peck, MD: Disclosed no relevant financial relationships.
Cynthia G. Pineda, MD: Disclosed no relevant financial relationships.
Patricia T. Tan, MD: Disclosed no relevant financial relationships.
Brionn K. Tonkin, MD: Disclosed no relevant financial relationships.
Kristin A. Wong, MD: Disclosed no relevant financial relationships.

No other planners, faculty or other individuals in control of content disclosed any relevant financial relationships.

FDA Disclosures
All faculty members for this activity have disclosed they do not intend to discuss or demonstrate any pharmaceutical or medical device for which FDA clearance has not been approved.